
| **Statistical Analyses	|  IV(s)  |  IV type(s) |  DV(s)  |  DV type(s)  |  Control Var | Control Var type  | Question to be answered | _H0_ | alpha | link to paper **| 
|:----------:|:----------|:------------|:-------------|:-------------|:------------|:------------- |:------------------|:----:|:-------:|:-------|
Chi Square	| 1, Number of patients (for each disease) | discrete | 1, number of events (for each disease) | discrete | 2, year, Study end point | categorical | 	 Do HER2+ patients elicited benefit in DFS , LRFS  and DDFS when compared to TNBC counterparts. | HER2+ patients elicited benefit in DFS , LRFS  and DDFS when compared to TNBC counterparts.  | 0.05 | [For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures](http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0083646) |
  |||||||||
  
